细胞角蛋白5/6、P63蛋白、细胞角蛋白7、甲状腺转录因子1免疫组织化学染色指标在非小细胞肺癌鉴别诊断中的应用

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (30 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To study the effect of immunohistochemical staining indexes of cytokeratin 5/6, P63 protein, cytokeratin 7 and thyroid transcription factor 1 in the diagnosis of non-small cell lung cancer.Methods From October 2018 to October 2020, 40 cases of bronchoscopic biopsy of lung lesions of patients with non-small cell lung cancer and 40 cases of bronchoscopic biopsy of lung lesions of patients with chronic obstructive pulmonary disease confirmed by treatment in Jiangxi Chest Hospital were selected, and 40 cases of bronchoscopic biopsy of normal lung tissue of patients were selected, which were divided into the study group 1, the study group 2 and the control group.Immunohistochemical staining was used to detect the positive expression of cytokeratin 5/6, P63 protein, cytokeratin 7 and thyroid transcription factor 1 in the three groups, and the detection results of the four indexes of cytokeratin 5/6, P63 protein,cytokeratin 7 and thyroid transcription factor 1 were compared among the three groups.Results The positive expression rates of cytokeratin 5/6, P63 protein, cytokeratin 7 and thyroid transcription factor 1 in the study group 1 were higher than those in the study group 2, the differences were statistically significant (P＜0.05).The positive expression rates of cytokeratin 5/6, P63 protein, cytokeratin 7 and thyroid transcription factor 1 in the study group 2 were higher than those in the control group, the differences were statistically significant (P＜0.05).Conclusion The positive expression rate of cytokeratin 5/6, P63 protein, cytokeratin 7 and thyroid transcription factor 1 in patients with non-small cell lung cancer are significantly higher than those in patients with chronic obstructive pulmonary disease and healthy people,which can be used as an important basis for screening and diagnosis of non-small cell lung cancer.

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LI Fei-mei
	WANG Wu-ming
	ZHAO Long

Cite this article:

LI Fei-mei,WANG Wu-ming,ZHAO Long. Application of immunohistochemical staining indexes of cytokeratin 5/6,P63 protein, cytokeratin 7, thyroid transcription factor 1 in the differential diagnosis of non-small cell lung cancer[J]. 中国当代医药, 2021, 28(29): 98-100.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2021/V28/I29/98

[2]	贺荣芝，刘川，蔡婧，等.非小细胞肺癌EGFR、ALK、ROS1基因突变和临床病理特征分析[J].临床与实验病理学杂志，2019，35（7）：843-845.
[3]	郭华，齐宗利，张海祥，等.非小细胞肺癌组织EGFR/ALK/ROS1 基因联合检测的临床意义[J].现代检验医学杂志，2018，33（6）：17-20.
[4]	张坦，王艺曈，方翼.非小细胞肺癌靶向治疗药物的研究现状[J].中国临床药理学杂志，2017，33（11）：1054-1057.
[5]	郭雅琪，赵志军，师志云，等.微滴数字PCR 在非小细胞肺癌EGFR、ALK、ROS1 基因联合检测中的应用价值[J].宁夏医科大学学报，2019，41（11）：1101-1107.
[1]	吴菡，孙苏安，刘海燕，等.非小细胞肺癌EGFR 基因突变与EML4-ALK 融合基因的表达及其临床病理特征[J].实用医学杂志，2018，34（13）：2119-2122.
[6]	白冬雨，张海萍，索文昊，等.非小细胞肺癌患者中EGFR突变、ALK 和ROS1 融合基因表达变化及其临床病理学意义[J].中国组织化学与细胞化学杂志，2019，28（1）：32-36.
[7]	李晓锋，张冠军，汪园园，等.非小细胞肺癌EGFR、ALK 和ROS1 基因联合检测及突变共存分析[J].分子诊断与治疗杂志，2018，10（6）：378-384.
[8]	黎谢梦丹，罗凯，吴顺芳，等.华南地区非小细胞肺癌患者肿瘤组织EGFR，ALK 和ROS1 基因突变分析[J].现代检验医学杂志，2017，32（5）：16-18.
[9]	杨澜，陈勃江，李镭，等.循环肿瘤DNA 甲基化在非小细胞肺癌中的研究进展[J].中华结核和呼吸杂志，2018，41（12）：967-970.
[10]	王晓莉，葛晓松，刘彦魁，等.EGFR/ALK/ROS1 三联检测在非小细胞肺癌中的临床意义[J].临床与实验病理学杂志，2018，34（10）：1135-1137.
[11]	王婷婷，李忠华，李慧峰，等.非小细胞肺癌中YAP1、SRPX2 的表达与微血管密度及预后的相关性分析[J].临床与实验病理学杂志，2020，36（3）：264-269.
[12]	段楚骁，付圣灵，付向宁.CK5/6、P63、TTF-1 和CK8/18在NSCLC 组织中的表达及意义[J].华中科技大学学报（医学版），2015，44（2）：147-151，175.
[13]	王建国，史春云，王建飞，等.癌组织TTF-1、CK7 及p63蛋白检测对不同病理类型NSCLC 的鉴别诊断价值[J].山东医药，2016，56（45）：60-62.
[14]	徐晓艳，杜华，宝鲁日，等.非小细胞肺癌活检标本中CK7、TTF-1、NapsinA、CK5/6 及P63 的表达及其意义[J].诊断病理学杂志，2015，22（11）：688-691.
[15]	陆雁，姚依勍，窦同海，等.液态活检在非小细胞肺癌中的应用及对中医肺癌研究的启示[J].检验医学与临床，2017，14（21）：370-371.